New resource available from the National Asthma Council Australia

20 Dec 2018

AMA members are advised that the National Asthma Council Australia has released a new evidence-based resource for primary care health professionals to help explain the latest treatment options for patients with severe asthma.

The Monoclonal antibody therapy for severe asthma information paper was developed based on the latest available evidence and implications for practice in primary care.

Monoclonal antibody therapies provide new options for treating patients with severe asthma. The therapy can reduce flare-ups, improve asthma symptoms and quality of life, and reduce corticosteroid requirements in patients with severe asthma.

The paper notes that patients still require usual asthma care from their GP. GPs should continue to check adherence and inhaler technique with patients.

More information and resources are available on the National Asthma Council Australia website.

Latest treatment options for patients with severe asthma

Monoclonal antibody therapy for severe asthma information paper